Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors reported that both finasteride and oral contraceptives with drospirenone had a significant therapeutic effect on women with polycystic ovary syndrome, leading to pregnancies in both treatment groups.

This study observed that women using combined oral contraceptives experienced more nausea, vomiting, and hair loss, while those on Depo-Provera were more likely to gain weight.

This article reviews the problem of acne and hirsutism in women, highlighting the effectiveness of combined oral contraceptives containing drospirenone and levomefolate calcium in managing these conditions and polycystic ovary syndrome, but no new clinical results are reported.

This study found that self-reported use of finasteride or oral contraceptives did not reduce the incidence of renal cancer in participants of the PCLO trial.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after six months, compared to those containing levonorgestrel.

This article discusses treatments for androgenic manifestations using cyproterone acetate alone or with estrogens, but it does not provide new clinical results.

This study found that Anovlar effectively reduced pain in severe dysmenorrhea cases and regulated cycles in oligomenorrhea patients, but some side effects and occasional treatment failures were reported.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

This article reviews clinical and treatment aspects of hyperandrogenism in women, emphasizing the roles of diagnostic practices, combined oral contraceptives, and cyproterone acetate, but introduces no new findings.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

This study found that a low estrogen-containing oral contraceptive normalized hormone levels and improved symptoms in women with polycystic ovary disease, with minimal side effects reported.

This study found that a low-dose oral contraceptive containing dienogest provides effective contraception, improves cycle stability, and may reduce excessive scalp and skin oiliness, with high user satisfaction.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This study found that ATP may help reduce ribociclib-induced skin damage in rats by mitigating biochemical changes associated with oxidative stress.

This study concluded that combining letrozole with cabergoline improved ovulation and clinical pregnancy rates in patients with polycystic ovarian syndrome and hyperprolactinemia compared to letrozole alone.

This article reviews pivotal trials and recent findings in chemoprevention for breast, prostate, and colorectal cancers, emphasizing its potential and the importance of further research, public education, and partnerships, but reports no new results.

This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.

This study found that oral contraceptives containing cyproterone acetate improved the overall quality of life in PCOS patients more than those containing levonorgestrel after 6 months of treatment.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after 6 months compared to those containing levonorgestrel.